CSRxP Briefing Covers Impact of Affordability Crisis, Drug Company’s Price-Hiking Practices and Bipartisan, Market-Based Solutions The Campaign for Sustainable Rx Pricing (CSRxP) hosted a briefing, “Prescription for Change: Why Drug Prices Are Out-of-Control and How to Fix It,” on Wednesday. CSRxP was joined for the briefing by a panel of leaders representing hospitals, physicians, health […]
Price Hikes Fuel Sky-High Earnings For Brand Name Giants As millions of Americans continue to grapple with the economic impact of the COVD-19 pandemic, the first earnings reports for the fourth quarter of 2020 from Big Pharma demonstrate that hiking prices on American patients continues to be a profitable practice for the industry. Yesterday, brand […]
Unjustified Rx Price Increases Cost American Patients & Health System Billions Big Pharma repeatedly hikes prices on brand name drugs without making any improvements to those medications. That’s the finding of a new analysis conducted by the Institute for Clinical and Economic Review (ICER). The report found that drug companies hiked prices on seven popular […]
Second Major Round of Pandemic Price Increases Underscores Urgency for Congress to Hold Drug Companies Accountable In case you missed it, Big Pharma hiked prices on at least 629 prescription drugs in just the first week of the New Year. Brand name giants Pfizer, GlaxoSmithKline and Sanofi were among the companies who increased prices on […]
Part IV: Escalating Assault on 340B Program for Providers Serving America’s Most Vulnerable Before the COVID-19 pandemic, more than 58 million Americans struggled to afford their prescription drugs. Now, the ongoing economic impact of the public health crisis continues to leave millions of American workers, families and seniors struggling just to stay afloat. Meanwhile, prescription […]
Part III: Angling to Price-Gouge American Public on COVID-19 Treatments Taxpayers Paid to Develop Before the COVID-19 pandemic, more than 58 million Americans struggled to afford their prescription drugs. Now, the economic impact of the COVID-19 crisis continues to leave millions of American workers, families and seniors struggling just to stay afloat. Meanwhile, prescription drug […]
Part II: Gaming the System to Undermine Competition at the Expense of American Patients Before the COVID-19 pandemic, more than 58 million Americans struggled to afford their prescription drugs. Now, the ongoing economic impact of the public health crisis continues to leave millions of American workers, families and seniors struggling just to stay afloat. Meanwhile, […]
Part I: Sticking with Price-Hiking “Business-as-Usual” During Pandemic Before the COVID-19 pandemic, more than 58 million Americans struggled to afford their prescription drugs. Now, the ongoing economic impact of the public health crisis continues to leave millions of American workers, families and seniors struggling just to stay afloat. Meanwhile, prescription drug prices continue to rise, […]
In case you missed it, Big Pharma giant AstraZeneca announced plans to acquire rare disease drug maker Alexion Pharmaceuticals in a $39 billion merger. AstraZeneca, the maker of blockbuster cholesterol medication Crestor, notched nearly $25 billion in revenue in 2019, while Alexion, best known for manufacturing one of the world’s most expensive rare disease medications, […]
Administration Should Abandon Misguided Policy That Rewards Drug Companies’ Price-Gouging and Anti-Competitive Tactics With Massive Bailout On Monday, the Trump Administration took a step toward enacting a misguided policy aimed at eliminating prescription drug rebates in Medicare Part D called the Rebate Rule by sending the measure to the Office of Management and Budget (OMB) […]